Selecta Biosciences Stock Forecast, Price & News

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SELB shares have increased by 5.2% and is now trading at $3.25.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Selecta Biosciences.

Wall Street analysts have given Selecta Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Selecta Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Selecta Biosciences.

Selecta Biosciences, Inc. (NASDAQ:SELB) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.03. The firm had revenue of $4.65 million for the quarter, compared to analysts' expectations of $3.75 million.
View Selecta Biosciences' earnings history.

7 brokerages have issued 12-month target prices for Selecta Biosciences' shares. Their forecasts range from $2.50 to $13.00. On average, they expect Selecta Biosciences' share price to reach $6.75 in the next twelve months. This suggests a possible upside of 107.7% from the stock's current price.
View analysts' price targets for Selecta Biosciences.

Selecta Biosciences saw a increase in short interest in the month of October. As of October 30th, there was short interest totaling 10,580,000 shares, an increase of 18.2% from the October 15th total of 8,950,000 shares. Based on an average daily trading volume, of 2,680,000 shares, the short-interest ratio is presently 3.9 days.
View Selecta Biosciences' Short Interest.

Some companies that are related to Selecta Biosciences include Ligand Pharmaceuticals (LGND), Athenex (ATNX), Endo International (ENDP), Indivior (INVVY), MacroGenics (MGNX), Phathom Pharmaceuticals (PHAT), Amneal Pharmaceuticals (AMRX), Intercept Pharmaceuticals (ICPT), Epizyme (EPZM), Retrophin (RTRX), Constellation Pharmaceuticals (CNST), Zogenix (ZGNX), Cytokinetics (CYTK), Kiniksa Pharmaceuticals (KNSA) and Nkarta (NKTX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

(SELB) raised $64 million in an IPO on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Selecta Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Mangrove Partners (5.36%), BlackRock Inc. (4.12%), Wasatch Advisors Inc. (1.93%), State Street Corp (1.11%), Vivo Capital LLC (0.88%) and Point72 Asset Management L.P. (0.37%). Company insiders that own Selecta Biosciences stock include Amir Nashat, Carsten Brunn, Timothy A Springer and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences.

SELB stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Mangrove Partners, Point72 Asset Management L.P., Wasatch Advisors Inc., Jane Street Group LLC, Morgan Stanley, Arrowstreet Capital Limited Partnership, and Virtus ETF Advisers LLC.
View insider buying and selling activity for Selecta Biosciences.

SELB stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., AQR Capital Management LLC, JPMorgan Chase & Co., State Street Corp, Wells Fargo & Company MN, Squarepoint Ops LLC, Charles Schwab Investment Management Inc., and Verdence Capital Advisors LLC. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences.

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SELB stock can currently be purchased for approximately $3.25.

Selecta Biosciences has a market capitalization of $351.10 million and generates $6.68 million in revenue each year. The company earns $-55,350,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.

The official website for Selecta Biosciences is selectabio.com.

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]